PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP worked with collaborators at Akcea Therapeutics, Inc., to conduct a retrospective analysis using Medicare claims data to identify cardiovascular conditions within 3 years prior to a transthyretin amyloidosis (ATTR) diagnosis. Findings show Medicare beneficiaries with ATTR have considerable cardiovascular conditions prior to diagnosis. Awareness of characteristic cardiovascular symptoms could lead to earlier diagnosis and prompt intervention. Results were presented as a poster at the virtual Heart Failure Congress 2021, and can be viewed here.